Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Head & Neck 2

Conditions

Prostatic Neoplasms 172Breast Neoplasms 24Neoplasms 13Leiomyoma 11Polycystic Ovary Syndrome 5Prostate Adenocarcinoma 3Neoplasm Metastasis 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Adenocarcinoma 3Salivary Gland Neoplasms 2Rare Diseases 2Myofibroma 2Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Hodgkin Disease 2Breast Neoplasms, Male 2Uveal Melanoma 1Uterine Neoplasms 1Urogenital Neoplasms 1Stage I Prostate Adenocarcinoma AJCC v7 1Sleep Apnea, Obstructive 1Skin Neoplasms 1Skin Diseases 1Sexual Dysfunctions, Psychological 1Sexual Dysfunction, Physiological 1Salivary Gland Neoplasm Duct 1Respiratory Tract Diseases 1Recurrence 1Puberty, Precocious 1

Interventions

Cisplatin 18Docetaxel 17Cetuximab 12Carboplatin 12Magnetic Resonance Spectroscopy 10pembrolizumab 9Radiotherapy 9Paclitaxel 8Erlotinib Hydrochloride 8Trastuzumab 7Gemcitabine 7Biopsy 7Specimen Handling 6Radiotherapy, Intensity-Modulated 6Radiotherapy, Conformal 5Radiosurgery 5Fluorodeoxyglucose F18 5Chemotherapy, Adjuvant 5Capecitabine 5Vorinostat 4Taxes 4Sorafenib 4Nivolumab 4Bevacizumab 4sargramostim 3Radiation 3Platinum 3N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine 3Lapatinib 3Irinotecan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Salivary Gland Neoplasms × Leuprolide × Clear all
NCT05669664 2026-05-13

Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers

National Cancer Institute (NCI)

Phase 2 Active not recruiting
21 enrolled
Head & Neck

Salivary Gland Neoplasms

NCT06145308 2026-04-02

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Peking Union Medical College

Phase 2 Recruiting
39 enrolled
Head & Neck

Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡